NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial | Biotech Hunter

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 5, 2018

Study Completion Date

March 5, 2018

Conditions

Chronic Kidney DiseaseAcute BleedingCerebrovascular Stroke

Interventions

DEVICE

Watchman

If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart

DRUG

Continued therapy with the prescribed oral anticoagulant

If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)

Trial Locations (1)

L8L 2X2

Hamilton General Hospital, Hamilton